News

CyteQuest publishes new article in Biomedical Microdevices

January 2024: CyteQuest publishes an article featuring the capabilities of our electroporation platform for flexible, 8-channel multiplexed optimization in Biomedical Microdevices titled, “A multiplexed microfluidic continuous-flow electroporation system for efficient cell transfection.” Available here.

CyteQuest presents at the 2023 BIO International Convention

June 2023: Supported by NIH SEED, CyteQuest showcases itself to potential partners and investors at the BIO International Convention in Boston, MA.

 

CyteQuest presents at the 2023 ASGCT Annual Meeting

May 2023: CyteQuest presents its technology and transfection data to the cell and gene therapy community at the ASGCT Annual Meeting in Los Angeles, CA. Download our poster below.

 

CyteQuest publishes new article in Scientific Reports

April 2023: CyteQuest publishes an article featuring the capabilities of its proprietary flow technology in Scientific Reports titled, “Scalable continuous-flow electroporation platform enabling T cell transfection for cellular therapy manufacturing. Available here.

CyteQuest presents at the Cornell NanoScale Facility's 2022 Annual Meeting

October 2022: CyteQuest engages with the local nanoscale community at Cornell University and presents its proprietary flow electroporation chip design at the CNF 2022 Annual Meeting

CyteQuest presents at BPI's Biotech Week Boston 2022

September 2022: CyteQuest showcases data from transfection of primary T cells in a poster presentation at Biotech Week Boston in the Cell & Gene Therapy Manufacturing section. Download our poster below.

CyteQuest receives $0.2 million grant from NIH

July 2022: CyteQuest is awarded $0.2 million SBIR Phase I grant from the National Institute of General Medical Sciences, a division of the National Institutes of Health to develop an adaptable and scalable platform for cellular therapy. Read more.

CyteQuest raises $1.1 million in new equity investment

November 2020: In pursuit of transforming non-viral cell engineering, CyteQuest secures $1.1 million in new equity investment to enable development of its proprietary flow electroporation technology. Read more.

Downloads

Scroll to Top